var data={"title":"Instant glucose and intravenous dextrose: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Instant glucose and intravenous dextrose: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6009?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-patient-drug-information\" class=\"drug drug_patient\">see &quot;Instant glucose and intravenous dextrose: Patient drug information&quot;</a> and <a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Instant glucose and intravenous dextrose: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50306670\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pfizer Extended Expiration Dates for Emergency Syringe Shortages</span>\n      <span class=\"collapsible-date\">- updated November 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has alerted health care providers of extended expiration dates for certain injectable drug products manufactured by Hospira (a Pfizer company) which may be used beyond the labeled expiration dates to assist with the ongoing critical shortages of injectable drugs used in critical care. Select lot numbers of atropine sulfate injection, dextrose 50%, epinephrine injection, and sodium bicarbonate are eligible for use beyond the labeled expiration date if they have been and will continue to be stored according to the labeled conditions<b>. </b></p>\n        <p style=\"text-indent:0em;\">Further information, including specific products, lot numbers, and extended expiration dates, may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPGtnB1wPEGG5AqBctyC78FXNni9GZNAqH+dg03OunIQVFis/VBQ2KMfj5sKJ1X0d3K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=8711\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm</a><b>.</b></p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158911\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dextrose Thermoject System [DSC];</li>\n      <li>Glucose Nursette [OTC];</li>\n      <li>Glutol [OTC];</li>\n      <li>Glutose 15 [OTC] [DSC];</li>\n      <li>Glutose 45 [OTC] [DSC];</li>\n      <li>Good Start 5% Glucose Water [OTC];</li>\n      <li>Insta-Glucose [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158922\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote, Hypoglycemia;</li>\n      <li>\n        Intravenous Nutritional Therapy</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158912\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glucose tolerance test (diagnostic test for diabetes):</b> Glutol: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">One-step (ADA 2018a): 75 g as single dose to a <b>fasting patient;</b> assess plasma glucose 2 hours after dose in nonpregnant adults or 1 and 2 hours after dose in pregnant women</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Two-step (ADA 2018a): Pregnant women:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First step: 50 g as a single dose to a <b>nonfasting patient</b>; assess plasma glucose 1 hour after dose; if levels &ge;130 mg/dL proceed to 100 g oral glucose tolerance test (<b>Note:</b> Cutoffs of &ge;135 or &ge;140 mg/dL have also been recommended; increased sensitivity and decreased specificity have been associated with use of a lower cutoff).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second step: 100 g as a single dose to a <b>fasting patient; </b>assess plasma glucose at 1, 2, and 3 hours after dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoglycemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 to 25 g (40 to 100 mL of 25% solution or 20 to 50 mL of 50% solution); repeat as needed in severe cases.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The Society of Critical Care Medicine suggests that blood glucose &lt;70 mg/dL (or &lt;100 mg/dL in neurologic injury patients) be treated immediately by discontinuing insulin therapy (if receiving) and administering 10 to 20 g (20 to 40 mL of 50% solution) IV; repeat blood glucose measurement in 15 minutes with repeat dextrose administration as necessary; avoid overcorrection (Jacobi 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 15 to 20 g as a single dose; repeat in 15 minutes if self-monitoring of blood glucose (SMBG) shows continued hypoglycemia. Once the SMBG returns to normal, a meal or snack should be consumed to prevent recurrence of hypoglycemia (ADA 2018b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia (adjunctive treatment) (off-label use): </b>IV: 25 g dextrose (50 mL D50W) over 5 to 30 minutes; administer with regular insulin 10 units; repeat as needed (AHA [Vanden Hoek 2010]; Allon 1990)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158919\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Instant glucose and intravenous dextrose: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoglycemia: Note:</b> Doses may be repeated in severe cases:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, intraosseous:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Dextrose 25% solution: 0.5 to 1 g/kg/dose (2 to 4 mL/kg/dose of 25% solution); maximum dose: 25 g/dose (AAP [Hegenbarth 2008]; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Dextrose 50% solutions: 0.5 to 1 g/kg/dose (1 to 2 mL/kg/dose of 50% solution); maximum dose: 25 g/dose (AAP [Hegenbarth 2008]; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Children and Adolescents: 15 to 20 g as a single dose; repeat in 15 minutes if hypoglycemia persists (ADA 2018b)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia, treatment (off-label use):</b> Infants, Children, and Adolescents: IV: 0.5 to 1 g/kg/dose (using 25% or 50% solution) combined with regular insulin over 15 to 30 minutes; dose may be repeated; in some cases, a continuous IV infusion may be necessary. <b>Note:</b> Usual ratio is 1 unit insulin for every 4 to 5 g dextrose (ACLS [Vanden Hoek 2010]; Fuhrman 2011; Hegenbarth 2008; Lehnhardt 2011; Masilamani 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062956\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158895\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutose 15: 40% (37.5 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutose 45: 40% (112.5 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutose 15: 40% (37.5 g [DSC]) [lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Insta-Glucose: 77.4% (31 g) [contains fd&amp;c red #40, methylparaben, propylparaben, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutol: 100 g/180 mL (180 mL) [lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dextrose Thermoject System: 5% (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/mL (10 mL); 5% (25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, 1000 mL); 10% (250 mL, 500 mL, 1000 mL); 20% (500 mL); 30% (500 mL); 40% (500 mL); 50% (50 mL, 500 mL, 1000 mL [DSC], 2000 mL [DSC]); 70% (500 mL, 1000 mL, 2000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucose Nursette: 5% (59 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Good Start 5% Glucose Water: 5% (88.7 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158884\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158898\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Must be swallowed to be absorbed (see Warnings/Precautions).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravenous: Injectable is not for SubQ or IM administration; concentrated dextrose solutions for peripheral venous administration must be diluted (maximum concentration: 12.5%); in emergency situations only, 25% and 50% dextrose have been used peripherally; for direct IV infusion, infuse at a maximum rate of 200 mg/kg over 1 minute; continuous infusion rates vary with tolerance and range from 4.5 to 15 mg/kg/minute; hyperinsulinemic neonates may require up to 15 to 25 mg/kg/minute infusion rates. Refer to indication-specific infusion rates in dosing for detailed recommendations.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">Vesicant (at concentrations &ge;10%); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hyaluronidase:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Dextrose 10%:</b> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Reynolds 2014; Zenk 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Dextrose 50%:</b> Injection of a total of 1 mL (150 units/mL) as five separate 0.2 mL injections administered along the leading edge of erythema has been used successfully (Wiegand 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158897\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypoglycemia: Treatment of hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Glucose tolerance test (Glutol): Oral glucose tolerance test for diagnosis of diabetes mellitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>5% and 10% solutions:</i> Fluid replacement/calories: Provision of calories and/or fluid replacement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>25% (hypertonic) solution:</i> Hypoglycemia: Treatment of acute symptomatic episodes of hypoglycemia in infants and children to restore depressed blood glucose levels</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>50% (hypertonic) solution: </i> Hyperinsulinemia, insulin shock: Treatment of insulin-induced hypoglycemia (hyperinsulinemia or insulin shock)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&ge;10% solutions:</i> Nutritional support: Infusion after admixture with other intravenous nutrients (eg, amino acids, fat emulsion) for nutritional support</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28843783\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Intravenous: 25% and 50% hypertonic solutions: Hyperkalemia (adjunctive): Treatment of hyperkalemia when used with concomitant insulin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158927\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Glutose may be confused with Glutofac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (hypertonic solutions &ge;20%) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Inappropriate use of low sodium or sodium-free intravenous fluids (eg D<sub>5</sub>W, hypotonic saline) in pediatric patients can lead to significant morbidity and mortality due to hyponatremia (ISMP 2009).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158889\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Localized phlebitis, phlebitis, venous thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Confusion, loss of consciousness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration, glycosuria, hyperglycemia, hyperosmolar syndrome, hypervolemia, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction (including anaphylaxis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158901\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Injectable: Hypersensitivity to corn or corn products; hypertonic solutions in patients with intracranial or intraspinal hemorrhage, diabetic coma, or delirium tremens, especially if dehydrated; severe dehydration; glucose-galactose malabsorption syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158887\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Vesicant (at concentrations &ge;10%); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperglycemia: An unexpected rise in blood glucose level in an otherwise stable patient may be an early symptom of infection. Rapid administration of hypertonic solutions may produce significant hyperglycemia, glycosuria, and shifts in electrolytes; this may result in dehydration, hyperosmolar syndrome, coma, and death especially in patients with chronic uremia or carbohydrate intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Severe hypersensitivity, including anaphylaxis, has been reported with dextrose infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypokalemia: Administration of potassium free IV dextrose solutions may result in significant hypokalemia, particularly if highly concentrated dextrose solutions are used; monitor closely and/or add potassium to dextrose solutions for patients with adequate renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyponatremia: Administration of low sodium or sodium-free IV dextrose solutions may result in significant hyponatremia or water intoxication in pediatric patients; monitor serum sodium concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; hyperglycemia and glycosuria may be functions of the rate of administration of dextrose; to minimize these effects, reduce the rate of infusion; addition of insulin may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperkalemia: The use of dextrose with insulin for the treatment of hyperkalemia achieves a rapid reduction in serum potassium concentrations by redistributing potassium intracellularly; however, this effect is transient (lasts up to 2 hours) and does not remove potassium body stores. Consider the use of other therapies aimed at increasing potassium elimination (eg, sodium polystyrene sulfonate, hemodialysis) (Elliott 2010; Khilnani 1992; Kraft 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Very low birth weight infants: Excessive or rapid dextrose administration in very low birth weight infants has been associated with increased serum osmolality and possible intracerebral hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Oral forms: Do not use oral forms in unconscious patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abrupt withdrawal: Rebound hypoglycemia may be associated with abrupt withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Hypertonic solutions (&gt;10%) may cause thrombosis if infused via peripheral veins; administer hypertonic solutions via a central venous catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parenteral nutrition: Patients receiving parenteral nutrition may be at risk of infections, refeeding syndrome, and parenteral nutrition associated liver disease (especially preterm infants).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299170\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158890\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8711&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158892\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (injection, infusion) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14207749\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with dextrose injection. In women with hyperemesis gravidarum who cannot tolerate oral liquids for prolonged periods or who are clinically dehydrated, intravenous hydration that includes dextrose is recommended. Due to potential maternal complications, enteral therapy is preferred over parenteral if nutrition support is required. Total parenteral nutrition (which may include dextrose) should be reserved for use in women with severe nausea and vomiting not responsive to medical therapy (ACOG 153 2015). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9835684\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;\">Some products may contain potassium and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158893\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood glucose, serum electrolytes, I &amp; O, caloric intake. Monitor infusion site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158896\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Classification of hypoglycemia (ADA 2018b):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypoglycemia alert value (level 1): &le;70 mg/dL (sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinically significant hypoglycemia (level 2): &lt;54 mg/dL (sufficiently low to indicate serious, clinically important hypoglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hypoglycemia (level 3): No specific glucose threshold (hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glucose tolerance test (diagnostic test for diabetes) (ADA 2018a):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">One step (75 g dose [fasting]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-pregnant adults: </i>Plasma glucose &ge;200 mg/dL at 2 hours postdose meets criteria for diagnosis of diabetes in nonpregnant adults; repeat testing on a different day is indicated in the absence of unequivocal hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pregnant women: </i>Criteria for diagnosis of gestational diabetes is met when any of the following plasma glucose levels are met/exceeded: Fasting: 92 mg/dL; 1 hour postdose: &ge;180 mg/dL; 2 hours postdose: &ge;153 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Two-step (first dose: 50 g [nonfasting]; second dose: 100 g [fasting]): Pregnant women:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Following 50 g dose: If levels &ge;130 mg/dL at 1 hour postdose, proceed to 100 g oral glucose tolerance test (<b>Note:</b> Cutoffs of &ge;135 or &ge;140 mg/dL have also been recommended; increased sensitivity and decreased specificity have been associated with use of a lower cutoff).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Following 100 g dose, criteria for diagnosis of gestational diabetes is met if at least 2 of the following 4 plasma glucose levels are met/exceeded: Fasting &ge;95 or 105 mg/dL; 1 hour postdose: &ge;180 or 190 mg/dL; 2 hours postdose: &ge;155 or 165 mg/dL; 3 hours postdose: &ge;140 or 145 mg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158886\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dextrose, a monosaccharide, is a source of calories and fluid for patients unable to obtain an adequate oral intake; may decrease body protein and nitrogen losses; promotes glycogen deposition in the liver. When used in the treatment of hyperkalemia (combined with insulin), dextrose stimulates the transient uptake of potassium by cells, especially in muscle tissue, lowering serum potassium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158900\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Treatment of hypoglycemia: Oral: 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: Treatment of hyperkalemia: IV: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapidly from the small intestine by an active mechanism </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Metabolized to carbon dioxide and water </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 40 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323104\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Glucose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (10): $2.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Glutose 15 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40% (37.5 g): $3.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Insta-Glucose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">77.4% (31 g): $4.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (100 mL): $2.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (500 mL): $6.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (500 mL): $13.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30% (500 mL): $13.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40% (500 mL): $14.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50% (50 mL): $9.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70% (2000 mL): $20.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Glucose Nursette Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (59 mL): $1.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Good Start 5% Glucose Water Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (88.7 mL): $1.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158903\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ardeanutrisol G (CZ);</li>\n      <li>Dextrabbott (MX);</li>\n      <li>Dextralpha (MX);</li>\n      <li>Dextrevit (MX);</li>\n      <li>Dextrogel (GB);</li>\n      <li>Diasol 5 (KR);</li>\n      <li>Fima D5 (IN);</li>\n      <li>Fluidex-5 (QA);</li>\n      <li>Glucocemin (ES);</li>\n      <li>Glucolin (AR);</li>\n      <li>Glucosada (PT);</li>\n      <li>Glucosado (PT);</li>\n      <li>Glucose Braun (PL);</li>\n      <li>Glucosteril (DE, FI, RU);</li>\n      <li>Glucosum (PL);</li>\n      <li>Glucotem (AR);</li>\n      <li>Glukoza (PL);</li>\n      <li>Glukoza Braun (PL);</li>\n      <li>Hluran CL (UA);</li>\n      <li>Infusan D (IN);</li>\n      <li>Infusol D10 (LK);</li>\n      <li>Injectio Glucosi (PL);</li>\n      <li>Isodex (HU);</li>\n      <li>Kissimin (AR);</li>\n      <li>Marivelle (PH);</li>\n      <li>Nutrosa (AR);</li>\n      <li>Rapilose (GB);</li>\n      <li>Wida (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. <i>Kidney Int</i>. 1990;38(5):869-872.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/2266671/pubmed\" target=\"_blank\" id=\"2266671\">2266671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2015;126(3):e12-e24. doi: 10.1097/AOG.0000000000001048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/26287788/pubmed\" target=\"_blank\" id=\"26287788\">26287788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 2. Classification and Diagnosis of Diabetes: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S13-S27. doi: 10.2337/dc18-S002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/29222373/pubmed\" target=\"_blank\" id=\"29222373\">29222373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dextrose [prescribing information]. Lake Forest, IL: Hospira; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. <i>CMAJ</i>. 2010;182(15):1631-1635.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20855477/pubmed\" target=\"_blank\" id=\"20855477\">20855477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hadaway L. Infiltration and extravasation. <i>Am J Nurs</i>. 2007;107(8):64-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/17667395/pubmed\" target=\"_blank\" id=\"17667395\">17667395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice, &ldquo;Plain D5W or Hypotonic Saline Solutions Post-Op Could Result in Acute Hyponatremia and Death in Healthy Children,&rdquo; ISMP Medication Safety Alert, August 13, 2009. Available at http://www.ismp.org/Newsletters/acutecare/articles/20090813.asp</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobi J, Bircher N, Krinsley J, et al, &ldquo;Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients,&rdquo; <i>Crit Care Med</i>, 2012, 40(12):3251-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/23164767/pubmed\" target=\"_blank\" id=\"23164767\">23164767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khilnani P. Electrolyte abnormalities in critically ill children. <i>Crit Care Med</i>. 1992;20(2):241-250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/1737458/pubmed\" target=\"_blank\" id=\"1737458\">1737458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005;62(16):1663-1682.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/16085929/pubmed\" target=\"_blank\" id=\"16085929\">16085929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/21181208/pubmed\" target=\"_blank\" id=\"21181208\">21181208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lui K, Thungappa U, Nair A, John E. Treatment with hypertonic dextrose and insulin in severe hyperkalaemia of immature infants. <i>Acta Paediatr</i>. 1992;81(3):213-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/1511193/pubmed\" target=\"_blank\" id=\"1511193\">1511193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation - A Hazard of Intravenous Therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. <i>Arch Dis Child</i>. 2012;97(4):376-380.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/21920871/pubmed\" target=\"_blank\" id=\"21920871\">21920871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiegand R, Brown J. Hyaluronidase for the management of dextrose extravasation. <i>Am J Emerg Med</i>. 2010;28(2):257.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20159411/pubmed\" target=\"_blank\" id=\"20159411\">20159411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care [published corrections appear in <i>Circulation</i>. 2011;123(6):e239 and <i>Circulation</i>. 2011;124(15):e405]. <i>Circulation</i>. 2010;122(18 suppl 3):s829-s861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8711 Version 177.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50306670\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158911\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F158922\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F158912\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F158919\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062956\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158895\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F158884\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F158898\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F158897\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28843783\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158927\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158889\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158901\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158887\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299170\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158890\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158892\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14207749\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9835684\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F158893\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F158896\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158886\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F158900\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323104\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F158903\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8711|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-patient-drug-information\" class=\"drug drug_patient\">Instant glucose and intravenous dextrose: Patient drug information</a></li><li><a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-pediatric-drug-information\" class=\"drug drug_pediatric\">Instant glucose and intravenous dextrose: Pediatric drug information</a></li></ul></div></div>","javascript":null}